Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating

JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $33.00.

Debanjana Chatterjee’s rating is based on the promising longer-term data from Intellia Therapeutics’ ATTR-PN trial, which showed significant improvements in neuropathy symptoms over a 24-month period. The trial results highlighted that patients who previously did not respond to other treatments experienced improvements with Intellia’s therapy, suggesting a more profound reduction in TTR levels compared to existing options.
Despite the small sample size, the data indicated positive trends across various efficacy parameters, including quality of life and biomarker levels. While there were some safety concerns related to AST elevation, these were asymptomatic and resolved without intervention. The high efficacy and manageable safety profile position Intellia’s treatment as a competitive option in the ongoing Phase 3 trial, justifying the Buy rating.

According to TipRanks, Chatterjee is an analyst with an average return of -1.9% and a 28.85% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Opus Genetics, Tvardi Therapeutics, and KalVista Pharmaceuticals.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.